Streetbeat News

ATXI

Avenue Therapeutics, Inc.

https://www.avenuetx.com

Industry

Biotechnology

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Open

1.94

Mkt cap

3.7M

Volume

10K

High

1.96

P/E Ratio

0.05

52-wk high

26.48

Low

1.90

Div yield

N/A

52-wk low

1.60

Avenue Therapeutics' shares are trading lower following the announcement of a 1-for-75 reverse stock split of its common stock. This corporate action is typically undertaken by companies aiming to increase their share price by reducing the number of shares outstanding, which can have various implications for investors and the company's market perception.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 7:15 pm

Aon plc shares fell by 7.4% after reporting quarterly financial results below market expectations. Other stocks showed significant movement, with Biodexa Pharmaceuticals and Pineapple Energy among the top gainers, while iClick Interactive and Nuwellis were notable losers.

Portfolio Pulse from Avi Kapoor

April 26, 2024 | 5:56 pm

Trading for ATXI was halted at 7:50:00 p.m. ET due to pending news. The halt is a temporary measure until the news affecting the company is released.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:50 pm

U.S. stocks saw a slight decline with the S&P 500, Dow, and NASDAQ all falling. AT&T reported a slight revenue decrease but beat EPS estimates. BranchOut Food, Amesite, and B. Riley Financial shares surged following positive company news, while Evotec, Avenue Therapeutics, and iSun shares plummeted. Oil and gold prices fell, while copper and silver also saw declines.

Portfolio Pulse from Avi Kapoor

April 24, 2024 | 6:33 pm

Teledyne Technologies shares fell by 9% after reporting disappointing Q1 financial results and cutting FY24 EPS guidance. Other stocks showed significant movement, with notable gainers including Chicken Soup for the Soul Entertainment and BranchOut Food, and losers like Neo-Concept International and iSun.

Portfolio Pulse from Avi Kapoor

April 24, 2024 | 5:57 pm

U.S. stocks showed mixed performance with the Dow Jones falling over 100 points, while the NASDAQ rose slightly. Consumer discretionary shares led gains, while industrials fell. Ribbon Communications, BranchOut Food, and Amesite saw significant stock price increases following positive news, whereas Evotec, Avenue Therapeutics, and New Oriental Education & Technology experienced declines. Crude oil inventories dropped more than expected, impacting commodity markets.

Portfolio Pulse from Avi Kapoor

April 24, 2024 | 4:00 pm

Avenue Therapeutics Inc (NASDAQ:ATXI) shares plummeted 28.5% to $0.09 after announcing a 1-for-75 reverse stock split to meet Nasdaq's minimum bid price requirement. The split, effective April 26, will reduce outstanding shares to approximately 0.6 million. This move aims to maintain its Nasdaq listing by ensuring a minimum bid price of $1.00 per share.

Portfolio Pulse from Henry Khederian

April 24, 2024 | 3:39 pm

Nasdaq rose 0.5% with Tesla shares jumping 10% after Q1 results, despite missing earnings and sales expectations. BranchOut Food, Amesite, and Chicken Soup for the Soul Entertainment saw significant gains, while Evotec, Avenue Therapeutics, and GlucoTrack experienced sharp declines. The article also highlights sector movements, with consumer discretionary shares up and industrials down.

Portfolio Pulse from Avi Kapoor

April 24, 2024 | 2:30 pm

Avenue Therapeutics announced a reverse stock split, leading to its shares trading lower.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 1:09 pm

Avenue Therapeutics announced a 1-for-75 reverse stock split, effective April 26, 2024, with its common stock trading on a split-adjusted basis on the Nasdaq under the same ticker 'ATXI' and a new CUSIP number 05360L403.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 11:32 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.